Scopolamine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market is Segmented by Dosage Form (Injectables, Tablets, Transdermal Patches and Others), by Distribution Channel and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The market studied is expected to witness CAGR of 6% over the forecast period. The market growth is attributed to the increasing prevalence of motion sickness and growing awareness among the population. Psychological stress is one of the major contributing factors of motion sickness. These psychological factors affect intestinal sensitivity and alteration in the central nervous system. Also, the introduction of novel drug delivery systems such as transdermal patches and adaptation of these dosage forms are expected to bolster the market growth over the forecast period.

Furthermore, the growing number of travellers across the globe, increasing number of surgeries due to chronic conditions is expected to boost the market growth. However, misuse of scopolamine, side effects and stringent regulatory policies are expected to hamper the market growth over the forecast period.

Scope of the Report

Scopolamine is the anticholinergic agent that is used to reduce the secretions of certain organs. It is used in treatment for motion sickness and postoperative nausea and vomiting. It is sometimes also used before the surgery to decrease secretions such as saliva.

By Dosage Form
Transdermal Patches
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Transdermal Patches Anticipated to Grow at Significant Rate

Transdermal patches are widely used nowadays in the treatment of motion sickness. The transdermal patches are prefered due to ease of use, cost-effectiveness and availability. The patch is applied to the hairless skin behind the ear and is used to treat the motion sickness caused by the anaesthesia during the surgeries. According to the world health organization, about 234.2 million major surgeries are performed around the globe every year. Owing to the growing number of surgical interventions across the globe coupled with the launch of new products, the market for transdermal scopolamine patches are expected to grow at a significant rate.

Also, the growing number of domestic and international travellers around the globe and the usage of scopolamine to treat motion sickness during travelling expected to boost market growth over the forecast period.

Scopolamine Trends

North America is Expected to have Significant Market Share

North America region is anticipated to have significant market share owing to well-established healthcare infrastructure and the presence of key market players. Also, a growing number of surgeries in the region, an increasing number of travellers coupled with product launches are anticipated to boost the market growth over the forecast period. According to the U.S. Travel Association, U.S. domestic travel has increased by 1.9% in 2018, a total of 2.3 billion person-trips. The Asia Pacific region is expected to grow at significant rates owing to increased expenditure on healthcare, presence of medium and small-sized market players and growing medical tourism for the surgeries in the region.  

Scopolamine Market -  Growth Rate by Region - Image

Competitive Landscape

Global scopolamine market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. The companies operating in the market include Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd., and Alchem International Pvt. Ltd. among others.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Number of Surgical Interventions due to Chronic Diseases

      2. 4.2.2 Rising Healthcare Expenditure and Adaptation of Scopolamine

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects and Misuse of Scopolamine

      2. 4.3.2 Stringent Regulatory Policies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Dosage Form

      1. 5.1.1 Injectables

      2. 5.1.2 Tablets

      3. 5.1.3 Transdermal Patches

      4. 5.1.4 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc.

      2. 6.1.2 Baxter International Inc.

      3. 6.1.3 Myungmoon Pharm Co Ltd

      4. 6.1.4 Alchem International Pvt. Ltd.

      5. 6.1.5 Caleb Pharmaceuticals, Inc.

      6. 6.1.6 GlaxoSmithKline plc.

      7. 6.1.7 Phytex Australia

      8. 6.1.8 Fine Chemicals Corporation

      9. 6.1.9 Perrigo Company plc

      10. 6.1.10 Novartis International AG

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Scopolamine Market market is studied from 2018 - 2026.

The Scopolamine Market is growing at a CAGR of 6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd, Alchem International Pvt. Ltd., Caleb Pharmaceuticals, Inc. are the major companies operating in Scopolamine Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!